Promoting research partnerships to improve veterans’ health

NAVREF is proud to recognize Cohen Veterans Bioscience as our Champion Sponsor

NAVREF News Center

  • 7 May 2019 12:56 PM | Anonymous member (Administrator)

    The FY19 Defense Appropriation provides $5 million (M) to the Department of Defense Lupus Research Program (LRP)to support that support the full spectrum of research projects or ideas that specifically focus on scientific and clinical lupus issues, which, if successfully addressed, have the potential to make a major impact in lupus research.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

    FY19 LRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website.

    Applications submitted to the FY19 LRP must address at least one of the five Focus Areas listed below:

    • Understand lupus disease heterogeneity in risk of disease, presentation, clinical course, and outcomes including, but not limited to, biopsychosocial studies, personalized medicine, variation in treatment and its effects on patient outcomes, health economics, socioeconomic studies, environmental studies, and epidemiological.
    • Understand lupus disease heterogeneity including, but not limited to, progressive stages of lupus over time, strategies and technologies to subtype patients, and understanding lupus disease mechanisms. 
    • Improve quality of life of life of patients with lupus.
    • Understand how the underlying genetic components and gene environment interactions of lupus disease relate to clinical disease characteristics using functional genomic studies.
    • Determine the pathobiology of lupus in target human tissues including, but not limited to, imaging studies, genomics of lupus disease in particular tissues, and metabolomics and how understanding the underlying pathobiology will improve quality of life of patients.

     

    https://cdmrp.army.mil/funding/lrp

     

     

    Concept Award – preproposal due June 7, 2019

    Investigators at all academic levels

    ·        Preproposal is required; application submission is by invitation only.

    ·        Supports highly innovative, untested, potentially groundbreaking concepts in lupus research

    ·        Emphasis is on innovation

    ·        Clinical trials are not allowed

    ·        Preliminary data is not required

    ·       The maximum allowable funding for the entire period of performance is of $200,000 for total costs.

    ·       The maximum period of performance is year

     

    Impact Award - preproposal due June 7, 2019

    Investigators at or above Assistant Professor (or equivalent)

    ·        Preproposal is required; application submission is by invitation only.

    ·        Supports high-risk/high-reward research

    ·        Emphasis is on impact

    ·        Clinical trials are not allowed

    ·        Preliminary data is encouraged but not required

    ·       The maximum allowable funding for the entire period of performance is $525,000 in total costs

    ·       The maximum period of performance is 3 years

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

     

    For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the LRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

    Point of Contact:

    CDMRP Help Desk
    301-682-5507
    help@eBrap.org


  • 2 May 2019 11:25 AM | Anonymous member (Administrator)

    The FY19 Defense Appropriation provides $12 million (M) to the Department of Defense Reconstructive Transplant Research Program (RTRP) to support research projects that specifically address needs in the field of vascularized composite allotransplantation (VCA).  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

    The RTRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY19 RTRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in May 2019.  Pre-application and application deadlines will be available when the Program Announcements are released.  This pre-announcement should not be construed as an obligation by the government.

    Focus Areas:  To meet the intent of the FY19 RTRP Idea Discovery Award and Investigator-Initiated Research Award mechanisms, applicants must address at least one of the FY19 RTRP Focus Areas listed below:

    • ·         Reduce the risks of VCA-associated immunosuppression
    • o    Define the unique mechanisms of VCA immunogenicity
    • o    Develop novel approaches for improving VCA immune tolerance
    • o    Identify unique immunosuppression requirements for VCA compared to other solid organ transplants
    • ·         Develop reliable non-invasive methods or tools for monitoring VCA graft rejection
    • o    Develop reliable non-invasive biomarkers for monitoring chronic VCA graft rejection in a large animal model
    • o    Identify and/or validate new peripheral biomarkers for acute and chronic rejection
    • o    Develop assays or devices for clinical graft monitoring utilizing validated biomarkers
    • ·         Advance existing or develop innovative ex vivo tissue preservation strategies to extend the timeline between procurement and transplantation
    • o    Develop novel approaches and models for perfused, hypothermic, high subzero and low subzero, or static preservation strategies
    • o    Determine the extent to which VCA tissue preservation technology impacts VCA immunogenicity

     

    https://cdmrp.army.mil/pubs/press/2019/19rtrppreann

     

    Idea Discovery Award

    Investigators at or above the level of postdoctoral fellow (or equivalent)

    ·         Supports innovative, untested, high-risk/ potentially high-reward concepts, theories, paradigms, and/or methods.

    ·         Innovation is the most important review criterion.

    ·         Project should include a well-formulated testable hypothesis based on strong scientific rationale and study design.

    ·         Preliminary or published data that supports the rationale are strongly encouraged.

    ·         Preproposal is required; full application submission is by invitation only.

    • ·         Applications must address at least one of the FY19 RTRP Focus Areas.

    ·       Maximum funding of $500,000 for total costs (direct plus indirect costs).

    • ·       Maximum period of performance is 2 years.

     

    Investigator-Initiated Research Award

    Independent investigators at all academic levels (or equivalent)

    ·         Supports studies with the potential to make an important contribution to the reconstructive transplant research field, patient care, and/or quality of life.

    ·         Preproposal is required; full application submission is by invitation only.

    ·         Preliminary or published data are required.

    ·         Multiple PI Option supports synergistic partnerships among two to four investigators collaborating on a single application; multi-institutional collaborations are encouraged.

    • ·         Applications must address at least one of the FY19 RTRP Focus Areas.

    Individual PIs:

    ·       Maximum funding of $1 million (M) for total costs (direct plus indirect costs).

    ·       Maximum period of performance is 3 years.

    Multiple PI Option:

    ·       Maximum funding of $1.5M for total costs (direct plus indirect costs).

    Maximum period of performance is 3 years.

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural Funding Opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

     

    Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the RTRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 1 May 2019 2:08 PM | Anonymous member (Administrator)

    The FY19 Defense Appropriation provides $3.2 million (M) to the Department of Defense Duchenne Muscular Dystrophy Research Program (DMDRP) to support innovative, high-impact Duchenne muscular dystrophy research.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

    The DMDRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY19 DMDRP Program Announcement and General Application Instructions for the following award mechanism are anticipated to be posted on the Grants.gov website in June 2019.  Pre-application and application deadlines will be available when the Program Announcement is released.  This pre-announcement should not be construed as an obligation by the government.

    IMPORTANT:  All applications for the FY19 DMDRP Idea Development Award must address opportunities and challenges in the development of safe and effective macromolecular and cellular therapies that address primary pathology of DMD. Eligible therapeutic strategies include: gene therapy, genome editing, oligonucleotide therapies, exon skipping, protein therapeutics, and cell therapies.

    Studies proposed under this award may include:

    ·         Delivery to skeletal muscle and heart (ligand assisted, nanoparticles, identification of biological barriers to delivery, alternative vectors)

    ·         Immunosuppression, and other strategies to deal with neutralizing antibodies

    ·         Re-dosing

    ·         Targeting muscle stem cells

    ·         Cell based therapies, including but not limited to: selection of novel cell types, expansion, root of delivery, differentiation, and integration

    Studies proposed under this award should not include:

    • ·         Therapies addressing secondary pathology of DMD (fibrosis, inflammation, muscle atrophy, oxidative stress, mitochondrial defects, abnormal peripheral circulation)
    • ·         Small molecules
    • ·         Efficacy testing absence of mechanistic understanding,
    • ·         Evaluation of standard vectors or delivery technologies

     

    https://cdmrp.army.mil/pubs/press/2019/19dmdrppreann

     

    Idea Development Award

    Independent investigators at all academic levels (or equivalent).

    • ·         Supports the development of innovative, high-impact ideas that advance the understanding of DMD and ultimately lead to improved outcomes.
    • ·         Preliminary data relevant to the proposed project are required.
    • ·         Pre-application is required; application submission is by invitation only.
    • ·         Clinical trials or applications including a clinical trial aim are not allowed
    • ·         Individual PI:
    • ·         Maximum funding of $350 thousand (K) in total costs
    • ·         Maximum period of performance years

     

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

     

    Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the DMDRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 30 Apr 2019 3:14 PM | Anonymous member (Administrator)

    Click the image to go to the conference information page.

  • 26 Apr 2019 11:28 AM | Anonymous member (Administrator)

    The FY19 Defense Appropriation provides $10 million (M) to the Department of Defense Orthotics and Prosthetics Outcomes Research Program (OPORP) to support research that evaluates the comparative effectiveness of orthotic and prosthetic clinical interventions using patient-centric outcomes for Service members and Veterans who have undergone limb amputation.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

    The OPORP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY19 OPORP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in May 2019.  Pre-application and application deadlines will be available when the Program Announcements are released.  This pre-announcement should not be construed as an obligation by the government.

    OPORP awards are focused on outcomes-based best practices through analysis of the merits of prosthetic and orthotic device options currently available, not on the development of new or the improvement of existing technology.  The intent of the awards is to generate clinically useful evidence that will enhance and optimize patient outcomes.

    Focus Areas:  The OPORP will only consider applications that specifically address the critical needs of the orthotics and prosthetics outcomes research community in one or more of the FY19 Focus Areas.  The OPORP will solicit research applications that address at least one of the following FY19 Focus Areas:

    • Orthotic or Prosthetic Device Form:  Understand patient outcomes through the analysis and characterization of variables related to the form of currently available clinical options such as device size, shape, material, and/or configurations.
    • Orthotic or Prosthetic Device Fit:  Understand patient outcomes related to human-device interface and component connection through the analysis of variables in currently available clinical options that facilitate fit-related metrics such as comfort and/or usability.
    • Orthotic or Prosthetic Device Function:  Understand patient outcomes through the analysis of variables related to currently available device function such as device control, sensors, and passive or active response with respect to activities of daily living and other real-world activities.

    https://cdmrp.army.mil/pubs/press/2019/19oporppreann

    Clinical Research Award

    Independent investigators at all academic levels (or equivalent)

    ·      Funding Level 1 may support pilot research that has the potential to make significant advancement towards clinical translation. Preliminary data are allowed but not required.

    ·      Funding Level 2 is supported by preliminary data and has the potential to make significant impact towards clinical translation.

    ·      Animal studies are not allowed.

    ·      Clinical trials are not allowed.

    Funding Level 1:

    ·      Maximum funding of $350,000 for total costs

    ·      Maximum period of performance is years

    Funding Level 2:

    ·      Maximum funding of $1M for total costs

    ·      Maximum period of performance is years

    Clinical Trial Award

    Independent investigators at all academic levels (or equivalent)

    ·      Funding Level 1 may support pilot clinical trials for exploratory studies involving limited human exposure with the potential to make significant advancement towards clinical translation. Preliminary data are allowed but not required.

    ·      Funding Level 2 supports rapid implementation of clinical trials with the potential to make significant impacts on improving the health and well-being of Service members, Veterans, and other individuals with limb deficit.

    ·      Preclinical research is not allowed.

    Funding Level 1:

    ·      Maximum funding of $350,000 for total costs

    ·      Maximum period of performance is years

    Funding Level 2:

    ·      Maximum funding of $2M for total costs

    ·      Maximum period of performance is years

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the OPORP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 17 Apr 2019 1:57 PM | Anonymous member (Administrator)

    The FY19 Defense Appropriation provides $30 million (M) to the Department of Defense Spinal Cord Injury Research Program (SCIRP)to support innovative, high-impact spinal cord injury research. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate, manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

    FY19 SCIRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website.

    For FY19, SCIRP encourages applications that address the critical needs of SCI research and patient care in one or more of the following FY19 Focus Areas:

    • Neuroprotection
    • Biomarkers
    • Bladder dysfunction,  bowel dysfunction and neuropathic pain
    • Psychosocial issues relevant to SCI in  individuals with SCI or their caregivers
    • Rehabilitation and regeneration

    https://cdmrp.army.mil/funding/scirp

    Clinical Trial Award – Preproposal due May 29, 2019

    Independent investigators at all academic levels (or equivalent)

    ·    Fund Phase 0, I, or II clinical trials with the potential to have a major impact on treatment or management of spinal cord injury (SCI) and its consequences.

    ·    Applications must include at least two SCI consumer advocates as members of the research team.

    ·    Preliminary data relevant to the proposed trial required for all clinical trial applications.

    ·    Pre-application required; application submission is by invitation only.

    ·    The maximum allowable funding for the entire period of performance is of $3, 000,000 for direct costs.

    ·    Indirect costs may be proposed in accordance with the institutions’ negotiated rate agreement.

    ·      The maximum period of performance is years

    Investigator-Initiated Research Award – Preproposal due May 29, 2019

    Independent investigators at all academic levels (or equivalent)

    ·    Fund SCI-related research that has the potential to make an important contribution to SCI research and/or patient care, and/or quality of life.

    ·  Preliminary data required.

    ·  Clinical trials not allowed.

    ·  Pre-application required; application submission by invitation only.

    ·  The maximum allowable funding for the entire period of performance is $500,000 for direct costs.

    ·  Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

    ·  The maximum period of performance is 3 years.

    Translational Research Award – Preproposal due May 29, 2019

    Independent investigators at all academic levels (or equivalent)

    ·      Fund studies that accelerate the movement of promising ideas in SCI research into clinical applications.

    ·      Applications must include at least one SCI consumer advocate as a member of the research team.

    ·      Preliminary data required

    ·      The SCIRP TRA may include a pilot clinical trial where limited clinical testing of a novel intervention or device is necessary to inform the next step in the continuum of translational research.

    ·      Pre-application required; application submission by invitation only.

    ·      The maximum allowable funding for the entire period of performance is $1,250,000 for direct costs.

    ·      Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

    ·      The maximum period of performance is 3 years

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism is also on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the SCIRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

    Point of Contact:

    CDMRP Help Desk

    301-682-5507
    help@eBrap.org


  • 17 Apr 2019 1:57 PM | Anonymous member (Administrator)

    The FY19 Defense Appropriation provides $7.5 million (M) to the Department of Defense Epilepsy Research Program (ERP) to understand the causative links between traumatic brain injury (TBI) and epilepsy so that post-traumatic epilepsy (PTE) will be both preventable and treatable.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency, J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

    The ERP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY19 ERP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in May 2019.  Pre-application and application deadlines will be available when the Program Announcements are released.  This pre-announcement should not be construed as an obligation by the government.

    Applications should also address at least one of the ERP FY19 Focus Areas.  An application that proposes research outside of the FY19 Focus Areas is acceptable, as long as the applicant provides a strong rationale.  The Focus Areas will be mechanism-specific.

    The ERP FY19 Focus Areas are as follows:

    Basic Research: Tools intended to better inform or improve upon how post-traumatic epilepsy research can be performed:

    • Hardware and/or software platforms that will improve seizure detection, characterization, or diagnosis
    • Bioinformatics strategies, to include machine learning, that will improve access, annotation, curation and visualization of large and novel datasets from single or multiple sources
    • Development of new models or better characterization of existing etiologically relevant models for PTE
    • Improved characterization of the circuits involved in PTE

    Markers and Mechanisms:  Identifying markers or mechanisms via preclinical models that address PTE, which may include the following:

    • Biomarkers
    • Therapeutic targets for epilepsy prevention
    • Early detection
    • Diagnosis
    • Prognosis
    • Comorbidity
    • Mortality
    • Risk stratification

    Epidemiology:  Epidemiological characterization of PTE following TBI, which may include the following:

    • Risk factors such as demographics, genetics, anatomy, pathology, or type of injury
    • Differentiation of PTE and psychogenic non-epileptic seizures (PNES)
    • Outcomes including latency to epilepsy, comorbidities, and mortality
    • Pre-existing conditions including psychological and psychiatric risk factors
    • Treatment and healthcare outcomes research

    Longitudinal Studies:  Studies of the natural evolution of PTE, which may include the following:

    • Seizure frequency and severity
    • Demographics, genetics, anatomy, pathology, or type of injury
    • Comorbidities (e.g., depression, functional deficits, sleep disorders, major illness)
    • Latency between type of injury and PTE
    • Mortality
    • Treatment and healthcare outcomes research
    • Quality of life of individuals with PTE and their caregivers

    https://cdmrp.army.mil/pubs/press/2019/19erppreann

    Idea Development Award

    Level I:  The Principal Investigator must be at or above the level of postdoctoral fellow (or equivalent), but below the level of Assistant Professor (or equivalent).  

    Level II:  The Principal Investigator must be an independent investigator at or above the level of Assistant Professor (or equivalent).

    Intent:  The intent of the FY19 ERP IDA is to solicit novel, innovative research to understand the magnitude and underlying mechanisms of PTE.

    ·      Level I is intended to support high-risk or high-gain research from researchers at or above the level of a post-doctoral fellow (or equivalent). 

    ·      Level II is intended to support a more mature, hypothesis-driven research project.

    The following Focus Areas are open to both Levels I and II:

    ·      Basic Research

    ·      Epidemiology

    ·      Markers and Mechanisms

    ·      Longitudinal Studies

    ·      Preliminary data, while not required, are encouraged for both levels.

    ·      Research considering a pharmacologic intervention is specifically discouraged under this mechanism.

    Level I:

    ·      Maximum funding of $300,000 for direct costs (plus indirect costs).

    ·      Maximum period of performance is 3 years.

    ·      Indirect costs may be proposed in accordance with the institution's rate agreement.

    Level II:

    ·      Maximum funding of $500,000 for direct costs (plus indirect costs).

    ·      Maximum period of performance is 3 years.

    ·      Indirect costs may be proposed in accordance with the institution's rate agreement.

    Research Partnership Award

    The PI must be an independent investigator at or above the level of Assistant Professor (or equivalent).

    Intent:  To create an avenue for collaborative research partnerships between/among investigators to address a research problem or question in a manner that would be unachievable through separate efforts. 

    ·      Level I is intended to support preclinical or pre-validation research

    ·      Level II is intended to support research requiring access to a patient cohort for a prospective study.

    Applications must include clearly stated plans for interactions between the partners. The plans must include communication, coordination of research progress and results, and data sharing between all investigators and organizations participating in the project.

    The following Focus Areas are open to both Levels I and II:

    ·      Epidemiology

    ·      Markers and Mechanisms

    ·     Longitudinal Studies

    ·     Preliminary data are required

    ·     Research considering a pharmacologic intervention is specifically discouraged under this mechanism.

    Level I:

    ·      Maximum funding of $1.3M for total costs.

    ·      Maximum period of performance is 3 years.

    ·      Indirect costs may be proposed in accordance with the institution's rate agreement.

    Level II:

    ·      Maximum funding of $2.0M in total costs.

    ·      Maximum period of performance is 4 years.

    ·      Indirect costs may be proposed in accordance with the institution's rate agreement.

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the ERP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 17 Apr 2019 1:56 PM | Anonymous member (Administrator)

    The FY19 Defense Appropriation provides $15 million (M) to the Department of Defense Peer Reviewed Alzheimer’s Research Program (PRARP) to support research which addresses the long-term consequences of traumatic brain injury (TBI) as they pertain to Alzheimer’s disease (AD) and related dementias (ADRD).  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency, J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

    The PRARP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY19 PRARP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in May 2019.  Pre-application and application deadlines will be available when the Program Announcements are released.  This pre-announcement should not be construed as an obligation by the government.

    FY19 PRARP Overarching Challenges and Focus Areas:

    All applications for FY19 PRARP Program Announcements must address at least one of the following FY19 Overarching Challenges.  The FY19 Overarching Challenges will be award mechanism-specific. 

    FY19 PRARP Overarching Challenges are listed below.

    PRARP FY19 Overarching Challenges

    Paucity of Research Resources:  The paucity of research resources and models to examine the interrelationship between TBI and subsequent AD/ADRD for the military, Veteran, and civilian communities and translate these findings

    Paucity of Clinical Studies:  The paucity of clinical studies to examine the interrelationship between TBI and subsequent AD/ADRD for the military, Veteran, and civilian communities

    Diagnostics and Prognostics:  The need for technologies, tests, surveys, questionnaires, devices, biomarkers, or analyses to detect TBI and sequelae to include AD/ADRD utilizing new and/or pre-existing datasets

    Epidemiology:  The paucity of epidemiological research to examine the interrelationship between TBI, risk and resiliency factors, and subsequent AD/ADRD for the military, Veteran, and civilian communities

    Quality of Life:  The need for technologies, assessments, interventions, or devices to benefit individuals living with the common symptoms of TBI and/or AD/ADRD

    Family and Care Support:  The need for technologies, assessments, interventions, or devices that enhance the lives of those providing care and families of individuals living with the common symptoms of TBI and/or AD/ADRD

    In addition to addressing one or more of the specified FY19 Overarching Challenges, applications should also address at least one of the following FY19 Focus Areas in support of the FY19 Overarching Challenges.  An application that proposes research outside of the FY19 Focus Areas is acceptable, as long as the applicant provides a strong rationale.  The Focus Areas will be award mechanism-specific.

    The PRARP FY19 Focus Areas are listed below.

    PRARP FY19 Focus Areas

    Mechanisms of Pathogenesis:  Identification of contributing mechanisms to include circuit dysfunction associated with TBI and subsequent AD/ADRD

    Biomarkers:  Development of methods to diagnose, prognose, or characterize neurological changes or risk/resiliency factors associated with TBI and subsequent AD/ADRD

    Quality of Life:  Research intended to alleviate, stabilize, or characterize the symptoms, or deficits, common to TBI and AD/ADRD

    Family and Caregiver Support: Research intended to reduce the burden of care on the caregivers or families of individuals living with the common symptoms or deficits of TBI and AD/ADRD

    Epidemiology:  Utilize new and existing studies and datasets to examine the relationships between risk and resiliency factors for TBI and subsequent AD/ADRD

    Novel Target Identification:  Basic research (non-human) directly leading to identification of new targets for the development of existing or new investigational medicines, drugs, or agents for TBI and subsequent AD/ADRD

    Nonpharmacological Interventions and Devices:  Research into non-medication-based interventions and devices to improve quality of life or caregiving for those living with the common symptoms of TBI and AD/ADRD

    Bioinformatics:  Tools, including machine learning, to access, annotate, curate, store, and visualize large existing or novel datasets, e.g., multimodal magnetic resonance imaging (MRI), other imaging techniques, surveys, questionnaires, and diagnostics for TBI and subsequent AD/ADRD

    The following is a summary of the FY19 PRARP Program Announcements.  Three award mechanisms will be offered for FY19. 

    https://cdmrp.army.mil/pubs/press/2019/19prarppreann

    Convergence Science Research Award

    Level I:  The Principal Investigator (PI) must be an independent, early-career investigator within 3 years of his/her first independent faculty position (or equivalent).  

    Intent:  Support innovative or novel efforts to generate research resources, tools, or research efforts for researchers and/or practitioners in health sciences.

    • Funding Level I is intended to support early-career investigators within 3 years of their first independent faculty position, from any field or discipline.
    • Funding Level II is intended to support PIs at or above the level of assistant professor (or equivalent) from any field or discipline.

    Applications must address one or more of the following FY19 PRARP Overarching Challenges:

    ·       Paucity of Research Resources

    ·       Paucity of Clinical Studies

    ·       Diagnostics and Prognostics

    ·       Epidemiology

    Applications should address at least one of the following FY19 PRARP Focus Areas:

    ·       Mechanisms of Pathogenesis

    ·       Biomarkers

    ·       Epidemiology

    ·       Novel Target Identification

    ·       Bioinformatics

    Research considering pharmacologic interventions is specifically discouraged under this mechanism.

    Preliminary data, while not required, are encouraged.Level II:  The PI must be an independent investigator at or above the level of Assistant Professor (or equivalent).

    Level I:

    ·      Maximum funding of $225,000 for direct costs (plus indirect costs).

    ·      Maximum period of performance is 3 years.

    ·      Indirect costs may be proposed in accordance with the institution's rate agreement.

    Level II:

    ·      Maximum funding of $500,000 for direct costs (plus indirect costs).

    ·      Maximum period of performance is 3 years.

    ·      Indirect costs may be proposed in accordance with the institution's rate agreement.

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the PRARP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 8 Apr 2019 3:06 PM | Anonymous member (Administrator)

    The FY19 Defense Appropriation provides $22 million (M) to the Department of Defense Gulf War Illness Research Program (GWIRP)to support research addressing Gulf War Illness pathobiology, diagnosis, and treatment.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

    The GWIRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY19 GWIRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in May 2019.  Pre-application and application deadlines will be available when the Program Announcements are released.  This pre-announcement should not be construed as an obligation by the government.

     

    https://cdmrp.army.mil/pubs/press/2019/19gwirppreann

    Idea Award

    Independent investigators at all academic levels

    ·        Preproposal is required; application submission is by invitation only.

    ·        Supports high-risk/high-reward research in the earliest stages of development that will contribute to markers or treatments for Gulf War illness (GWI).

    ·        Emphasis is on impact and innovation; applications must articulate the pathway to making a clinical impact for Veterans with GWI, even if a clinical impact is not an immediate outcome.

    ·        Preliminary data not required.

    ·        Biorepository Contribution Option supports additional costs associated with submission of samples and data to the GWIRP supported Boston Biorepository, Recruitment, and Integrative Network (BBRAIN).

    ·        Clinical trials not allowed.

    ·       Maximum funding of $150,000 for direct costs (plus indirect costs)

    ·       Biorepository Contribution Option: additional direct costs up to $20,000

    ·       Maximum period of performance is years

     

    Idea Development Award

    Independent investigators at all academic levels

    ·        Preproposal is required; application submission is by invitation only.

    ·        Supports applied research in GWI that is aimed at continued expansion and validation of markers and treatments that are supported by evidence in the GWI field. 

    ·        Preliminary data and/or strong rationale required.

    ·        Biorepository Contribution Option supports additional costs associated with submission of samples and data to the GWIRP supported Boston Biorepository, Recruitment, and Integrative Network (BBRAIN).

    ·        Clinical trials are not allowed.

    ·       Maximum funding of $700,000 for direct costs (plus indirect costs)

    ·       Biorepository Contribution Option: additional direct costs up to $20,000

    ·       Maximum period of performance is 3 years

     

    Clinical Evaluation Award

    Independent investigators at all academic levels

    ·       Preproposal is required; application submission is by invitation only.

    ·       Supports small, proof-of-concept trials (pilot, first in human, Phase I-IIa), clinical trials, or larger statistically powered biomarker trials with the potential to have a significant impact on GWI.

    ·       Preliminary data required.

    ·       Biorepository Contribution Option supports additional costs associated with submission of samples and data to the GWIRP supported Boston Biorepository, Recruitment, and Integrative Network (BBRAIN).

    ·       Clinical Consortium Collaboration Option supports additional costs associated with collaboration with the Gulf War Illness Clinical Trials and Interventions Consortium (GWICTIC).

    ·      Maximum funding of $1,000,000 for direct costs (plus indirect costs)

    ·       Biorepository Contribution Option: additional direct costs up to $20,000

    ·       Clinical Consortium Collaboration Option: additional direct costs up to $200,000

    ·       Maximum period of performance is 3 years

     

    Therapeutic/Biomarker Trial Award

    Independent investigators at all academic levels

    ·       Supports large-scale, pivotal (Phase IIb or III) trials that revolutionize the clinical management of GWI.

    ·         Objective pharmacodynamic biomarkers to measure the biological effect of an investigational therapeutic or predictive/cohort-selective biomarkers that indicate whether a specific therapy will be effective in Veterans with GWI must be included in the trial design.

    ·       Substantial preliminary data in a GWI Veteran population required.

    ·       Investigators must have experience in successfully leading large-scale projects and demonstrated the ability to implement a clinical project successfully.

    ·       Biorepository Contribution Option supports additional costs associated with submission of samples and data to the GWIRP supported Boston Biorepository, Recruitment, and Integrative Network (BBRAIN).

    ·       Clinical Consortium Collaboration Option supports additional costs associated with collaboration with the GWIRP supported Gulf War Illness Clinical Trials and Interventions Consortium (GWICTIC).

    ·       Funding must be used to support a clinical trial.

    ·      Maximum funding of $5,000,000 for direct costs (plus indirect costs)

    ·       Biorepository Contribution Option: additional direct costs up to $20,000

    ·       Clinical Consortium Collaboration Option: additional direct costs up to $500,000

    ·       Maximum period of performance is 4 years

     

    Patient-Provider and Health Communications Award

    Independent investigators at or above the level of Assistant Professor

    ·       Preproposal is required; application submission is by invitation only.

    ·       Supports development of strategies to effectively communicate GWI research and clinical recommendations to public health professionals, policymakers, healthcare providers, Veterans with GWI, caregivers, or advocacy groups.

    ·       Maintenance and sustainment of the dissemination effort for continued awareness of GWI research and clinical findings to diverse audiences is an important review criterion.

    ·       Must include a consumer GWI advocate, who will be integral throughout the planning and implementation of the research project.

    ·       Clinical trials are not allowed.

    ·      Maximum funding of $700,000 for direct costs (plus indirect costs)

    ·      Maximum period of performance is 3 years

     

    New Investigator Award

    Transitioning Postdoctoral Fellow: Senior postdoctoral fellows with at least 3 years of postdoctoral training

    Early-Career Investigator:Independent investigators within 5 years of last training position

    New GWI Researcher:Established independent investigators who have received less than $300,000 in federally funded, non-mentored GWI research

    ·      Preproposal is required; application submission is by invitation only.

    ·      Encourages applications from early-stage and established investigators new to the field of GWI research.

    ·      Previous experience in GWI research is not required; however, collaborations with experienced GWI researchers is strongly encouraged.

    ·      Preliminary data are not required.

    ·       Biorepository Contribution Option supports additional costs associated with submission of samples and data to the GWIRP supported Boston Biorepository, Recruitment, and Integrative Network (BBRAIN).

    ·       Clinical trials are not allowed.

    ·      Maximum funding of $500,000 for direct costs (plus indirect costs)

    ·      Biorepository Contribution Option: additional direct costs up to $20,000

    ·      The maximum period of performance is 3 years

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the GWIRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 8 Apr 2019 3:05 PM | Anonymous member (Administrator)

    The FY19 Defense Appropriation provides $5 million (M) to the Department of Defense Lupus Research Program (LRP)to support that support the full spectrum of research projects or ideas that specifically focus on scientific and clinical lupus issues, which, if successfully addressed, have the potential to make a major impact in lupus research.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

    The LRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY19 LRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in April 2019.  Pre-application and application deadlines will be available when the Program Announcements are released.  This pre-announcement should not be construed as an obligation by the government.

    Applications submitted to the FY19 LRP must address at least one of the five Focus Areas listed below:

    • Understand lupus disease heterogeneity in risk of disease, presentation, clinical course, and outcomes including, but not limited to, biopsychosocial studies, personalized medicine, variation in treatment and its effects on patient outcomes, health economics, socioeconomic studies, environmental studies, and epidemiological.
    • Understand lupus disease heterogeneity including, but not limited to, progressive stages of lupus over time, strategies and technologies to subtype patients, and understanding lupus disease mechanisms. 
    • Improve quality of life of life of patients with lupus.
    • Understand how the underlying genetic components and gene environment interactions of lupus disease relate to clinical disease characteristics using functional genomic studies.
    • Determine the pathobiology of lupus in target human tissues including, but not limited to, imaging studies, genomics of lupus disease in particular tissues, and metabolomics and how understanding the underlying pathobiology will improve quality of life of patients.

     

    https://cdmrp.army.mil/pubs/press/2019/19lrppreann

     

     

    Concept Award

    Investigators at all academic levels

    ·        Preproposal is required; application submission is by invitation only.

    ·        Supports highly innovative, untested, potentially groundbreaking concepts in lupus research

    ·        Emphasis is on innovation

    ·        Clinical trials are not allowed

    ·        Preliminary data is not required

    ·       Maximum funding of $200,000 for total costs (direct plus indirect costs)

    ·       Maximum period of performance is year

     

    Impact Award

    Investigators at or above Assistant Professor (or equivalent)

    ·        Preproposal is required; application submission is by invitation only.

    ·        Supports high-risk/high-reward research

    ·        Emphasis is on impact

    ·        Clinical trials are not allowed

    ·        Preliminary data is encouraged but not required

    ·       Maximum funding of $525,000 for total costs (direct plus indirect costs)

    ·       Maximum period of performance is 3 years

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

     

    Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the LRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


1717 K ST NW Suite 900

Washington, DC 20006

P: 301-656-5005  |  admin@navref.org

Powered by Wild Apricot Membership Software